Compare HST & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HST | DVA |
|---|---|---|
| Founded | 1927 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 14.9B |
| IPO Year | 1998 | 2003 |
| Metric | HST | DVA |
|---|---|---|
| Price | $22.73 | $178.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | $20.75 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 9.6M | 936.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | 1.06 | ★ 6.86 |
| Revenue | $5,387,000,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $0.10 | $3.85 |
| Revenue Next Year | $1.09 | $3.07 |
| P/E Ratio | ★ $21.03 | $26.00 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $15.61 | $101.00 |
| 52 Week High | $25.71 | $247.49 |
| Indicator | HST | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 22.17 |
| Support Level | $20.92 | $145.58 |
| Resistance Level | $25.56 | $202.63 |
| Average True Range (ATR) | 0.59 | 8.05 |
| MACD | -0.32 | -7.32 |
| Stochastic Oscillator | 9.91 | 2.00 |
Host Hotels & Resorts owns 78 predominantly urban and resort upper-upscale and luxury hotel properties representing over 42,000 rooms, mainly in the United States. Host sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.